NCT01145209 2023-11-28
Ofatumumab-based Induction Chemoimmunotherapy in Previously Untreated Patients With CLL/SLL
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
Clinical Trials
10 trialsNCT02689141 2020-06-11
Sequential Regimen of Bendamustin-Debulking Followed by Ofatumumab and Ibrutinib in CLL Patients (CLL2-BIO)
German CLL Study Group
Phase 2 Completed
NCT01110031 2017-11-13
Ofatumumab Cardiac Repolarization (QTc) Study in Fludarabine-Refractory Chronic Lymphocytic Leukemia Subjects
GlaxoSmithKline
Phase 1 Completed
NCT01077622 2017-05-30
A Phase I/II, a Single Arm, Open-label Study of Ofatumumab (GSK1841157) in Patients With Previously Treated Chronic Lymphocytic Leukemia
GlaxoSmithKline
Phase 2 Completed
NCT01520922 2017-01-19
Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)
Novartis
Phase 2 Completed
NCT01563055 2015-08-10
A Phase I/II, Open-label Study of Ofatumumab Added to Chlorambucil in Previously Untreated Japanese Patients With Chronic Lymphocytic Leukemia
GlaxoSmithKline
Phase 2 Completed
NCT01453062 2014-07-08
Phase IV Observational Study in Chronic Lymphocytic Leukemia
GlaxoSmithKline
Completed
NCT00349349 2014-06-04
HuMax-CD20 in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Failing Fludarabine and Alemtuzumab
GlaxoSmithKline
Phase 2 Completed
NCT00802737 2014-05-14
Efficacy and Safety of Ofatumumab Retreatment and Maintenance Treatment in Patients With B-cell Chronic Lymphocytic Leukemia (CLL)
GlaxoSmithKline
Phase 4 Completed
NCT00410163 2014-02-10
BIFROST
GlaxoSmithKline
Phase 2 Completed